Ovarian cancer is one of the most lethal of women cancers and lack potent therapeutic options.There have many evidences demonstrate the Notch signaling has deregulation in variety of human malignancies.MK-0752 is a novel potent γ-secretase inhibitor and now assessed in clinical trial for treatment of several types of cancer,our objective was to investigate the anticancer effects and mechanisms of MK-0752 alone or combined with cisplatin in ovarian cancer.

Cell lines used:A2780,OVCAR3,SKOV3,HO8910PM,the effects of MK-0752 and cisplatin on cell proliferation was measured by MTT assay. The effect of combination treatment was examined by isobologram analysis.The distribution of cell cycle and cell apoptosis were analysed using PI and Annexin V-FITC/PI staining by flow cytometric analysis. The mechanism in biochemistry were analysed by using Western blot. Mouse xenograft model of A2780 was established to observe the anti-ovarian cancer effects in vivo setting, nude mice were randomized into four groups (n=6 per group) and treated every four days with control (solvent) group, MK-0752(25mg/Kg) group, Cisplatin(2mg/Kg)group, combination group(both of MK-0752 and cisplatin).

MK-0752 alone actively induced cell growth inhibition,G2/M phase cell cycle arrest and apoptosis with down-regulation of Notch1 and its downstream effectors including Hes1,XIAP,c-Myc and MDM2 in a dose- and time- dependent manner. Moreover, sequential combination of cispaltin prior to MK-0752 significantly promoted cell apoptosis and inhibited the subcutaneous xenograft growth of ovarian cancer in nude mice.

Our data supports the sequential combination of cispaltin prior to MK-0752 is a highly promising novel experimental therapeutic strategy against ovarian cancer.